Table 2.
Treatment-related side effects occurring in > 1 patient
| Toxicity | Total Events | N=26 | ||
|---|---|---|---|---|
| G1 | G2 | G3 | ||
| Anemia | 3 | 2 | 1 | |
| Fatigue | 16 | 11 | 4 | 1 |
| Anorexia | 5 | 3 | 2 | |
| Nausea | 14 | 12 | 2 | |
| Vomiting | 6 | 3 | 3 | |
| Diarrhea | 7 | 6 | 1 | |
| Constipation | 2 | 2 | ||
| Dyspepsia | 6 | 6 | ||
| Taste alteration | 2 | 1 | 1 | |
| Mucositis | 6 | 1 | 7 | |
| Pain-Abdomen NOS | 4 | 2 | 2 | |
| Hand-foot reaction | 20 | 9 | 9 | 2 |
| Rash | 2 | 1 | ||
| Headache | 5 | 4 | 1 | |
| Sensory neuropathy | 3 | 2 | 1 | |
Note: Number of worst grade adverse events possibly, probably, or definitely attributed to capecitabine during study drug administration. Toxicities are graded per the NCI CTCAE version 3 criteria. G1=Grade 1, G2=Grade 2, G3=Grade 3. NOS= not otherwise specified.